Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 44.5% in April

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 147,543 shares, a decline of 44.5% from the April 15th total of 265,805 shares. Based on an average trading volume of 38,559 shares, the short-interest ratio is presently 3.8 days. Currently, 0.8% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

ESLA has been the subject of a number of recent analyst reports. D. Boral Capital reissued a “buy” rating and set a $8.00 target price on shares of Estrella Immunopharma in a research note on Monday, February 9th. Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Estrella Immunopharma has a consensus rating of “Hold” and a consensus price target of $8.00.

Estrella Immunopharma Stock Down 7.9%

NASDAQ:ESLA traded down $0.10 during mid-day trading on Friday, reaching $1.11. The company’s stock had a trading volume of 27,998 shares, compared to its average volume of 38,334. Estrella Immunopharma has a 1 year low of $0.78 and a 1 year high of $3.15. The stock has a fifty day moving average of $1.35 and a 200-day moving average of $1.51. The firm has a market capitalization of $47.36 million, a PE ratio of -3.17 and a beta of 0.97.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Wednesday, March 18th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.17. On average, analysts expect that Estrella Immunopharma will post -0.39 earnings per share for the current year.

Institutional Trading of Estrella Immunopharma

Several hedge funds have recently modified their holdings of ESLA. Geode Capital Management LLC lifted its position in shares of Estrella Immunopharma by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after buying an additional 8,318 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Estrella Immunopharma by 1,045.7% during the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock valued at $191,000 after buying an additional 111,779 shares during the last quarter. State Street Corp lifted its position in shares of Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after buying an additional 20,900 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Estrella Immunopharma during the fourth quarter valued at about $88,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Estrella Immunopharma during the fourth quarter valued at about $43,000. 0.35% of the stock is owned by hedge funds and other institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.